Zantac Heartburn Medication
In October 2019, a class-action lawsuit was filed against Sanofi-Aventis U.S., Sanofi US Services, Chattem, Inc., and Boehringer Ingelheim Pharmaceuticals for allegedly failing to disclose that the over-the-counter heartburn medication Zantac exposes users to unsafe levels of the carcinogen N-Nitrosodimethylamine (NDMA). (Dimesky et al v. Sanofi-Aventis U.S., LLC, Sanofi US Services Inc., Chattem, Inc., and Boehringer Ingelheim Pharmaceuticals, Inc., Case No. 19-cv-1517, D. CT.)
Class-Action Tracker
The Latest
Fairlife Milk
Company’s animal welfare claims – and brand name – face increasing scrutiny.
CATrends: Baseball Ticket Prices
Consumers balk at hidden junk fees.
Benjamin Moore: Timeless
As years pass and life shifts, the walls around us quietly hold every moment.
Consumer Cellular
TINA.org uncovers the limits of this carrier’s “unlimited” data plans.
There Should Be a Price to Pay for Knowingly Lying to Consumers
Why TINA.org wants the Supreme Court to address proof of harm in Lanham Act cases.